Wednesday, July 6, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Atmospheric Science

Molecular imaging biomarker predicts response to CAR T cell therapy

June 13, 2022
in Atmospheric Science
0
Share on FacebookShare on Twitter

Vancouver, British Columbia, Canada (Embargoed until 3:00 p.m. PDT, Sunday, June 12, 2022)—A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes. The research was presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

Representative 18F-AlF-FAPI-74 PET/CT images showed statistical differences in tracer uptake between non-transduced (NTD) T cell-treated (left, M4916) and FAP CAR T cell-treated (right, M4917) animals.

Credit: Images created by Iris K. Lee, Department of Bioengineering and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Estela Noguera-Ortega and Maria Liousia, Thoracic Oncology Research Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Zebin Xiao, Leslie Todd and Ellen Puré, Department of Biomedical Sciences, School of Veterinary Medicine, Perel-man School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Kexiang Xu, Kimberly J. Edwards, and Mark A. Sellmyer, Department of Radiology, Perelman School of Med-icine, University of Pennsylvania, Philadelphia, Pennsylvania; and Steven Albelda, Thoracic On-cology Research Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, and Center for Cellular Immunotherapies, Perel-man School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Vancouver, British Columbia, Canada (Embargoed until 3:00 p.m. PDT, Sunday, June 12, 2022)—A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes. The research was presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

Chimeric antigen receptor T cell (CAR T) therapy is a treatment that involves removing T cells from a patient’s body, engineering them in a lab, and then returning the T cells to the body to fight the specified disease. This type of therapy has had marked success in treating blood cancers but has not been as effective in treating solid tumors.

“Our understanding of why CAR T therapies are not as effective in solid tumors could be advanced by measuring CAR T-targeted antigens, such as the fibroblast activation protein (FAP), which is overproduced in many types of solid tumors,” said Iris Lee, PhD candidate at the University of Pennsylvania. “In this study, we used 18F-AlF-FAPI-74 PET to image FAP with the goal of providing information that could aid in the development and optimization of FAP CAR T cell treatment for solid tumors.”

Several experiments were conducted as part of the study. In the first, an in vitro cell uptake experiment was performed to test the binding of the 18F-AlF-FAPI-74 tracer in FAP-expressing cells. Next, the tracer uptake was assessed in two different tumor xenograft models (mesothelioma and adenocarcinoma). Finally, researchers evaluated whether 18F-AlF-FAPI-74 could detect FAP clearance as a way to monitor response to FAP CAR T cell treatment.

The cell uptake experiment demonstrated highly specific binding of 18F-AlF-FAPI-74 to FAP. For both xenograft models, a significant increase in 18F-AlF-FAPI-74 uptake in the tumor was noted relative to background tissues (e.g. muscle and blood). 18F-AlF-FAPI-74 PET was also able to successfully detect and image clearance of FAP+ cells from the tumor following an FAP CAR T cell treatment.

“Our work highlights the potential role of 18F-AlF-FAPI-74 as a predictive and pharmacodynamic imaging biomarker to guide patient selection and monitor therapeutic response to FAP-targeted therapies,” noted Lee.

She added, “In the current era of precision medicine where cancer therapies can be tailored based on the presence or absence of a biomarker, molecular imaging tools have the potential to add value to clinical care by helping to accurately monitor the target of interest and stratify patients for certain therapy based on the target expression level.”

Abstract 892. “Monitoring Therapeutic Response to FAP CAR T Cells using [18F]AlF-FAPI-74 PET,” Iris K. Lee, Department of Bioengineering and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Estela Noguera-Ortega and Maria Liousia,  Thoracic Oncology Research Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Zebin Xiao, Leslie Todd and Ellen Puré, Department of Biomedical Sciences, School of Veterinary Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Kexiang Xu, Kimberly J. Edwards, and Mark A. Sellmyer, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Steven Albelda, Thoracic Oncology Research Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Link to Abstract

###

All 2022 SNMMI Annual Meeting abstracts can be found online.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.



Journal

Journal of Nuclear Medicine

Article Title

Monitoring Therapeutic Response to FAP CAR T Cells using [18F]AlF-FAPI-74 PET

Article Publication Date

12-Jun-2022

Tags: BiomarkerCARcellimagingmolecularpredictsresponsetherapy
Share26Tweet16Share4ShareSendShare
  • Neurovascular injury from SARS-CoV-2

    Small NIH study reveals how immune response triggered by COVID-19 may damage the brain

    71 shares
    Share 28 Tweet 18
  • Scientists discover cancer trigger that could spur targeted drug therapies

    68 shares
    Share 27 Tweet 17
  • COVID-19 fattens up our body’s cells to fuel its viral takeover

    99 shares
    Share 40 Tweet 25
  • Researchers uncover life’s power generators in the Earth’s oldest groundwaters

    67 shares
    Share 27 Tweet 17
  • Study shows convalescent plasma doesn’t benefit severely ill patients hospitalized with COVID-19

    65 shares
    Share 26 Tweet 16
  • Do early therapies help very young children with or at high likelihood for autism?

    82 shares
    Share 33 Tweet 21
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

COVID-19 fattens up our body’s cells to fuel its viral takeover

nTIDE May 2022 COVID Update: Uncertainty about inflation tempers good news for people with disabilities

The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 190 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....